Ferry Tristan, Gogos Charalambos, Soriano Alex, Blasi Francesco, Ansari Wajeeha, Kantecki Michal, Schweikert Bernd, Luna Gustavo, Bassetti Matteo
Infectious Diseases Department, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France.
Division of Infectious Diseases, Department of Internal Medicine, University of Patras, Patras, Greece.
Infect Drug Resist. 2024 Jul 4;17:2773-2783. doi: 10.2147/IDR.S455515. eCollection 2024.
Ceftaroline fosamil is approved for the treatment of complicated skin and soft tissue infections (cSSTI) and community-acquired pneumonia (CAP); however, data on its real-world use and effectiveness in Europe and Latin America are currently limited. This retrospective observational study assessed ceftaroline fosamil use and treatment outcomes in adults hospitalized with cSSTI or CAP treated with ceftaroline fosamil in a usual care setting in Europe and Latin America. Results for patients with cSSTI are reported.
Data from patients with cSSTI who received ≥4 consecutive intravenous ceftaroline fosamil doses up to May 31, 2019, were collected from sites in Brazil, Colombia, France, Greece, Italy, and Spain. Patient characteristics, clinical management, hospitalization information, microbiological diagnosis, and clinical responses were summarized descriptively. Healthcare resource use variables were evaluated by clinical response to ceftaroline fosamil.
Data for 132 patients were included (58.3% male; mean age 58.5 years). Most common lesions were cellulitis/fasciitis (62.1%), abscess (34.1%), and post-surgical wounds (19.7%). Pathogens most frequently identified were methicillin-resistant (18.2%) and methicillin-susceptible (17.4%). Median (range) ceftaroline fosamil treatment duration was 8 (2-60) days (daily doses of 1200 [400-2400] mg); 78 patients (59.1%) received monotherapy. In total, 75 (56.8%) patients had additional antibiotics after ceftaroline fosamil. Clinical response occurred in 118 (89.4%) patients. All-cause 30-day readmission occurred in 13 (9.8%) patients, and all-cause 30-day mortality in 7 (5.3%). Clinical response to ceftaroline was associated with >25% shorter length of hospital and intensive care stay, and with ~40% lower hospital costs, versus non-responders.
Ceftaroline fosamil was effective in treating adults with cSSTI and clinical response to ceftaroline fosamil was associated with reductions in healthcare resource use compared with non-responders, in Europe and Latin America.
NCT04198571.
头孢洛林酯已被批准用于治疗复杂性皮肤及软组织感染（cSSTI）和社区获得性肺炎（CAP）；然而，目前其在欧洲和拉丁美洲的实际使用情况及有效性数据有限。这项回顾性观察性研究评估了在欧洲和拉丁美洲常规治疗环境中接受头孢洛林酯治疗的cSSTI或CAP住院成人患者中头孢洛林酯的使用情况及治疗结果。本文报告了cSSTI患者的结果。
收集了来自巴西、哥伦比亚、法国、希腊、意大利和西班牙各研究点，在2019年5月31日前接受连续≥4剂静脉注射头孢洛林酯的cSSTI患者的数据。对患者特征、临床管理、住院信息、微生物学诊断和临床反应进行了描述性总结。通过对头孢洛林酯的临床反应评估医疗资源使用变量。
纳入了132例患者的数据（男性占58.3%；平均年龄58.5岁）。最常见的病变为蜂窝织炎/筋膜炎（62.1%）、脓肿（34.1%）和术后伤口（19.7%）。最常鉴定出的病原体是耐甲氧西林的（18.2%）和对甲氧西林敏感的（17.4%）。头孢洛林酯的中位（范围）治疗持续时间为8（2 - �0）天（每日剂量1200 [400 - 2400]毫克）；78例患者（59.1%）接受了单药治疗。总共有75例（56.8%）患者在使用头孢洛林酯后加用了其他抗生素。118例（89.4%）患者出现了临床反应。13例（9.8%）患者发生了30天全因再入院，7例（5.3%）患者发生了30天全因死亡。与无反应者相比，对头孢洛林酯有临床反应的患者住院和重症监护住院时间缩短>25%，住院费用降低约40%。
在欧洲和拉丁美洲，头孢洛林酯对治疗成人cSSTI有效，与无反应者相比，对头孢洛林酯的临床反应与医疗资源使用的减少相关。
NCT04198571。
